Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
US-8946239-B2 · Feb 3, 2015 · US
Pyrimidine compounds and pyrimido indole compounds and methods of use
US10233194B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10233194-B2 |
| Application number | US-201715479752-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 5, 2017 |
| Priority date | Aug 8, 2014 |
| Publication date | Mar 19, 2019 |
| Grant date | Mar 19, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH 2 , and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt, hydrate, or solvate thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of the formula: wherein R 1 is a methyl group, R 2 is hydrogen, R 3 is hydrogen, and R 4 is an alkyl group having from three to five carbon atoms, or a pharmaceutically acceptable salt or hydrate thereof. 2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula: wherein R 1 is a methyl group, R 2 is hydrogen, R 3 is hydrogen, and R 4 is an alkyl group having from three to five carbon atoms, or a pharmaceutically acceptable salt or hydrate thereof.
Assignees
Inventors
Classifications
Non-condensed quinolines and containing further heterocyclic rings · CPC title
Two nitrogen atoms · CPC title
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Ortho-condensed systems · CPC title
containing two hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10233194B2 cover?
- The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH 2 , and optionally comprising a pharmaceutically acceptable salt, hydrate, or solvate thereof. A method of treating a patient having cancer or a disease comprising a…
- Who is the assignee on this patent?
- Univ Holy Ghost Duquesne, Duquesne Unversity of the Holy Spirit
- What technology area does this patent fall under?
- Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).